Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Hence, researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

And we think this will give us, hopefully, a clear picture of potential dose response in ... And then in the second quarter, third quarter of this year, we will have the important summary judgment ...

The 437-patient study – reported in June – compared a 50 µg booster dose of ... start offering second boosters to the over-50s and vulnerable people from next month. "Moderna is working ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

H5N1 vaccines have been previously licensed, and millions are in the national stockpile. But even with the news of the country’s first human death due to bird flu, vaccination isn’t yet recommended.